{"name":"Trefoil Therapeutics, Inc.","slug":"trefoil-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPX2NmQ0t6MmxEb0tSdkpmYzA4ajIzdlNfNDVBSVhEd19RSENSalNOU0tyVUNadjRGNkdpUVhyazlLd1dXRl94S213REFKOVBsWWxYdFhoUlNxZFAtTTBJOUUyekVRUGI1OEMxSEhja2lGc2h3bDczWEVmSy1xY2owLVMtRnhMOXNiMG56UnN6SzdVVjJBa1hEYm1jNWNaWllOOVV5d0FZbWFjTGwtdVhFZ1RfR0UxSlVabjFPSnNyWjhVeV9kNHN1eGtaUWpNeDdMbExpT2x0ekhPSG9XalpXOTJKbFhhSC11SERITG5kNWRXSEtJbUFZOGxhRlF6ZFU1REZBMWxpUU91bkFxZVE?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Persistent Corneal Edema Market to Show Impressive Growth at a CAGR of 21.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Persistent Corneal Edema Market to Show Impressive Growth at a CAGR of 21.8% During the Forecast Period (2025-2034) | De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQR1Vta1E1b0dGcEZWQldWdFJSWWdIdVdzUVJfM0g3WkMxVHY0RjlBWWlnZHd4ajlhQ0hpX0Y3NEZEcUl1X1RueTR0ZUlXaW5ETDVfUXlVTkhNbV92Z09EUkNPdGltYTFYUGkxZ2hjR1BFUWhGbWhGZDE5ME0ydWZxWHpvS05TOUxKdk14WHlQeVN4QQ?oc=5","date":"2024-07-31","type":"trial","source":"Yahoo Finance","summary":"Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsight - Yahoo Finance","headline":"Fuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQQVpld2hXNUhFTEptcm1MZVJFellnal9IWVo5Mjd1UkVRb0tVY0pxV2hvSDd2Y2ZGZ0xXNU9zTDY4eGFjNEI5R1JuTmdmUW9WYldWM2pMekdKVE9jNXRmOUx6a25XUlNLQ241dnhGVnZTLWFscG5GbmRUbzJ0RkhWMEN0NzhfSk92MWl0OU9QWDlCUVJ0VXduWFl2NndMRTFNNkU1bU5KdU56QTVfbktBNU0zYURhblZCTEVZZDhiSGxFWEhtUlRyY1F3bTdrTC0ybTZmU05lWTd2clNvQThmYUtpRjhGZHF0bWl6cXVwYlNyWFU?oc=5","date":"2024-04-09","type":"regulatory","source":"PR Newswire","summary":"Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight - PR Newswire","headline":"Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1CNmFvLXd2TmVsOGFMQ1hvRlNNVkQ5WVd0cEtIQWtfYlR3YXUyTE83MF9SUEM1azRrcmRRMjJkdXB4Y2VSLXNQX3hMUFNFZ2lrYk83Y1pHOUpVVjFRYVMxbDc3ek5KYzFRaFk0MFN3?oc=5","date":"2023-09-01","type":"pipeline","source":"American Academy of Ophthalmology","summary":"Four Refractive Challenges - American Academy of Ophthalmology","headline":"Four Refractive Challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPS2FndFVUem9yUHRYbVlaQlEzMFhxWHRNYVY5S01XbWdBZ2VpTlpkclk4YTZ2MUdXREFkWTZleWdZZUNaTTVvLUc1U2JSdnpwTk41U0hvY2VDNTBPTVV3WUJvSkR4dU5oSXNmVHN5cG1SaFVFZDlLMElfRkJsMS1lYUdGQkJvcEtOZ2Q4VlR6Mm1aSGtPOVc0REVKcjQzYnM2RW16SGQxZmk4R3B1S0ZjNVVvMG94NHF5V0FpWU1IcDgxWDczYnFkYkxYSzcwTWk0ZHZ3MjBxTElxZmxESHlWRTFR?oc=5","date":"2020-02-10","type":"pipeline","source":"Business Wire","summary":"Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development - Business Wire","headline":"Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}